Combined ipilimumab, pembrolizumab and durvalumab for advanced solid tumors
Tests ipilimumab, pembrolizumab and durvalumab together in adults with advanced solid tumors.
Plain-language title generated from the registry record
Registry title: Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
Key facts
- Where
- Guangzhou, ChinaSee the site
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced solid tumors confirmed by tissue tests. It tests a combination of CTLA4, PD1 and PDL1 antibodies given by vein, artery or directly into the tumor.
- Age
- Above 18 years, up to 70 years. Expected survival over 3 months.
- Sex
- All sexes can join.
- Disease stage
- Advanced solid tumors (lung, liver, colorectal, pancreas, ovary, head and neck, breast, gastric, cervical or esophageal cancer). At least one tumor that can be measured by RECIST v1.1. Child-Pugh class A or B; ECOG score below 2.
- Earlier treatment
- Cannot have joined another drug or device trial within the last 4 weeks.
- Biomarker or test result
- Cancer must be confirmed by tissue or cell examination. Blood tests within 7 days must meet set limits (for example WBC at least 3.0×10E9/L, Hb at least 90g/L, PLT at least 50×10E9/L).
Main reasons for not taking part
- Ascites, hepatic encephalopathy or bleeding from esophageal or gastric varices
- Another tumor now or in the past
- Serious other disease, such as heart disease, poorly controlled diabetes or psychiatric disorders
- Pregnant or breastfeeding
- Allergy to contrast agent
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT05187338, who can take part
Where in China
- The second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Second Affiliated Hospital of Guangzhou Medical University
- Trial code
- NCT05187338
- Record updated
- 25 June 2024
- Original description
This trial is designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by infusion of CTLA4, PD1 and PDL1 antibodies combination through venous (IV), artery (IA) or intra-tumor (IT).Read full original descriptionShow less
Triplex CTLA4/PD1/PDL1 Checkpoint Inhibitors Combination Therapy for Advanced Solid Tumors
This trial is designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by infusion of CTLA4, PD1 and PDL1 antibodies combination through venous (IV), artery (IA) or intra-tumor (IT).
Inclusion: Cytohistological confirmation is required for diagnosis of cancer; Signed informed consent before recruiting; Age above 18 years with estimated survival over 3 months; Child-Pugh class A or B/Child score > 7; ECOG score < 2; Tolerable coagulation function or reversible coagulation disorders; Laboratory examination test within 7 days prior to procedure: WBC≥3.0×10E9/L; Hb≥90g/L； PLT ≥50×10E9/L；INR < 2.3 or PT < 6 seconds above control；Cr ≤ 145.5 umul/L；Albumin > 28 g/L；Total bilirubin < 51 μmol/L; At least one tumor lesion meeting measurable disease criteria as determined by RECIST v1.1; Birth control; Willing and able to comply with scheduled visits, treatment plan and laboratory tests.
Exclusion: Patients participated in clinical trials of equipment or drugs (signed informed consent) within 4 weeks; Any agents which could affect the absorption or pharmacokinetics of the study drugs; Patients accompany by ascites, hepatic encephalopathy and esophageal and gastric varices bleeding; Any serious accompanying disease, which is expected to have an unknown, impact on the prognosis, include heart disease, inadequately controlled diabetes and psychiatric disorders; Patients accompanied with other tumors or past medical history of malignancy; Allergic to contrast agent; Other conditions that investigator decides not suitable for the trial; Patients have poor compliance; Any contraindications for hepatic arterial infusion procedure:; A.Impaired clotting test (platelet count < 60000/mm3, prothrombin activity < 50%); B.Renal failure / insufficiency requiring hemo-or peritoneal dialysis. C.Known severe atheromatosis. D.Known uncontrolled blood hypertension (> 160/100 mm/Hg); Pregnant or lactating patients, all patients participating in this trial must adopt appropriate birth control measures during treatment.